Default company panoramic image


Genticel develops therapeutic solutions for women already infected by HPV before high grade lesions or cervical cancer occur.

  • Stage Concept Only
  • Industry Biotechnology
  • Location Labège, Midi-Pyrénées, France
  • Currency EUR
  • Employees 30
  • Website

Company Summary

Genticel is a clinical stage biotechnology company focused on developing multivalent vaccines against Human Papillomavirus (HPV) infections which are the known cause for several cancers including cervix carcinoma.


  • Default avatar
    Benedikt Timmerman
    Founder, Chief Executive Officer

    PhD University of Ghent, Belgium & MBA, INSEAD.
    20 years international career in Life Science Companies
    Previously Sr Director R&D of Novartis Seeds (1994 – 2000), member of EU Executive Committee (1995 – 2000) & member of Novartis Agribusiness (now Syngenta) global corporate Licensing and Acquisitions team (1997 – 2000)

  • Default avatar
    Martin Koch
    Chief Financial Officer

    Engineer, INAPG, France & MBA, INSEAD.
    20 years of international career in financial and operational management
    Previously, Sales Director Oncology Cephalon Pharma France (2006 – 2007) and Controlling and Finance Director functions at Elan & Zeneus Pharma UK (2001 – 2005)

  • Default avatar
    Marie-Christine Bissery
    Chief Scientific Officer

    PhD and Pharm. D Paris & Washington University;
    Academia: 7 years , Washington University, Michigan Cancer Foundation, Wayne State University Medical School
    Previously, International Director of Oncology (2007– 2008) and Deputy Head of Oncology (2005-2007), Sanofi-aventis; Sr Director Experimental Therapeutics and Translational Research, Aventis Pharma (2000-2004)

Previous Investors

  • Default avatar
    Idinvests Partners, Edmond de Rothschild Investment Partners,
    Default avatar
    InnoBio fund, The FSI and CDC Entreprises,
    Default avatar
    Amundi Private Equity Funds (Amundi PEF), IRDI